New breast cancer drug wins FDA approval after slashing progression risk by nearly 40%
PositiveU.S News

The recent FDA approval of Inluriyo, an oral estrogen receptor antagonist developed by Eli Lilly, marks a significant advancement in breast cancer treatment. This drug has demonstrated the ability to reduce the risk of disease progression by nearly 40%, offering new hope for patients. Such a breakthrough not only enhances the quality of life for those battling breast cancer but also represents a crucial step forward in cancer research and treatment options.
— Curated by the World Pulse Now AI Editorial System